Skip to Main Content

Paper Details

A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
Sleep
4
2022
Hot Flash-associated Insomnia, Insomnia, Suvorexant, VMS, WASO, chronic insomnia, estrogen, insomnia disorder, orexin, orexin receptor, orexin receptors, person, suvorexant, vasomotor symptom, women
Author NameAffiliation
Hadine JoffeHarvard Medical School
Hadine JoffeConnors Center for Women's Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School
Hadine JoffeBrigham and Women's Hospital, Harvard Medical School
  • 1 - 3

Datasets

Release 1.2